Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.61 |
| ▸ | F10 | P00742 | 11/20 | 0.59 |
| ▸ | F2 | P00734 | 4/20 | 0.59 |
| ▸ | PYGL | P06737 | 6/20 | 0.56 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11888195 | 0.91 | SMYD3 (0.61) | SMYD3F10F2PYGLEHMT2 | |
| SCHEMBL4363306 | 0.90 | SMYD3 (0.63) | SMYD3F10F2PYGLEHMT2 | |
| SCHEMBL4360291 | 0.90 | SMYD3 (0.63) | SMYD3F10F2PYGLEHMT2 | |
| SCHEMBL4360293 | 0.90 | SMYD3 (0.63) | SMYD3F10F2PYGLEHMT2 | |
| SCHEMBL12101161 | 0.88 | SMYD3 (0.61) | SMYD3F10F2PYGLEHMT2 | |
| SCHEMBL11888160 | 0.88 | SMYD3 (0.61) | SMYD3F10F2PYGLEHMT2 | |
| SCHEMBL14318622 | 0.88 | SMYD3 (0.61) | SMYD3F10F2PYGLEHMT2 | |
| SCHEMBL17149805 | 0.87 | SMYD3 (0.62) | SMYD3F10F2PYGLEHMT2 | |
| SCHEMBL12669925 | 0.86 | F10 (0.71) | SMYD3F10F2PYGL | |
| SCHEMBL1860174 | 0.86 | SMYD3 (0.67) | SMYD3F10F2PYGLEHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227789-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227789-A1 | ETHYLENEDIAMINE DERIVATIVES | F2, ECE1, MLLT1 | SMYD3 995/4885F10 126/4885F2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.